European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

Clarivate

OCTOBER 31, 2023

What do the years 2001, 2007, 2014, and 2022 have in common? These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. In short, the biotech bubble had burst. Pfizer’s $11.6 Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Clarivate

MAY 8, 2023

That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. Timing is everything. You have to be patiently impatient,” he said.

Biopharma 52

Biopharma Sales Networking Marketing 52

Clarivate

APRIL 24, 2023

For pharmas and medtechs, this fast-evolving payer/provider landscape means companies will need to stay on top of emerging access points in order to bring new drugs, devices, diagnostics and procedures to market and ensure that patients can access them. Key acquisitions by U.S. healthcare organizations Company Founded Type No.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

European Pharmaceutical Review

DECEMBER 12, 2023

Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. As a biotech, what work does Innate Pharma do in the biopharma industry?

Pharma 124

Pharma Engineering Safety Patients 124

Pharmaceutical Technology

AUGUST 26, 2008

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. ”

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40